Today’s PBAC outcome on Selpercatinib is a significant step forward for Australians living with medullary thyroid carcinoma (MTC). NECA Medical Ambassador Professor Stephen Clarke says continued progress depends on a system that can keep pace with innovation. “Australia is fortunate to have the PBS, ensuring equitable access to approved medicines. Decisions like this highlight...
Click on the "Follow" button below and you'll get the latest news from NeuroEndocrine Cancer Australia via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
NeuroEndocrine Cancer Australia title: NeuroEndocrine Cancer Australia